Batoclimab (FCGRT) - Research Grade Biosimilar

Batoclimab (HBM9161) is fully human antibody targeting neonatal Fc receptor (FcRn) . It can accelerate the degradation of autoantibodies in patients with optic neuromyelitis spectrum diseases and other autoimmune diseases. FcRn expression is upregulated by pro-inflammatory cytokines (such as TNF-α) and prolongs the half-life of IgG and serum albumin by reducing lysosomal degradation in endothelial cells and bone marrow-derived cells. Blocking the FcRn-IgG interaction can accelerate the degradation of autoantibodies and mitigate the onset of various pathogenic IgG-mediated autoimmune diseases, including myasthenia gravis, thyroid eye disease, optic neuromyelitis spectrum disease, and immunity Thrombocytopenia.

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.